Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Investigating the Survival Benefit of Adding Thoracic Radiotherapy to Durvalumab (MEDI4736) Immunotherapy Plus Chemotherapy in Extensive Stage Small-cell Lung Cancer

NCT05223647 is registered in ClinicalTrials.gov with Norwegian University of Science and Technology as lead sponsor.

NCT NCT05223647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05223647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Investigating the Survival Benefit of Adding Thoracic Radiotherapy to Durvalumab (MEDI4736) Immunotherapy Plus Chemotherapy in Extensive Stage Small-cell Lung Cancer
Lead sponsor
Norwegian University of Science and Technology
Phase
Phase 3
Overall status
Terminated
Start date
January 11, 2022
Completion date
September 4, 2025
Enrollment
239 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer